Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.
Tirzepatide在2型糖尿病管理中的概況:設計、發展和治療中的地位。
Expert Opin Pharmacother 2023-03-29
A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Tirzepatide - 一種新型雙重 GLP1 和 GIP 激動劑的安全性系統性回顧:其安全性檔案是否可接受?
Front Endocrinol (Lausanne) 2023-04-18
Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
停用新型葡萄糖依賴性胰島素促分泌肽(GIP)和葡萄糖樣肽-1(GLP-1)受體激動劑 Tirzepatide 後對血紅蛋白A1c(HbA1c)和體重的影響:單一中心病例系列研究。
Cureus 2023-10-26
A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
對雙糖依賴性胰島素促泌肽/葡萄糖樣胰高血糖素-1受體激動劑 Tirzepatide 引起全身過敏反應之病例報告。
Cureus 2024-02-02
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
Tirzepatide透過長效活化腸骨肽激素受體,調節脂肪細胞營養代謝的調控。
Cell Metab 2024-06-15
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.
在FDA不良事件報告系統(FAERS)數據庫中對Tirzepatide進行的實際世界數據分析。
Front Pharmacol 2024-06-24